RNTX PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

RNTX ▲ +3.88% at T+20d

SHORT call ✗ call lost -3.88% · α vs SPY +1.40% · entry $1.03 → $1.07

Next anchor: T+60d in 6w

Last close $0.9580 (close Jun 12) · +6.99% from $1.03 entry (call sign-flipped)

Entry anchored
Apr 30, 2026
via day open

T+1d

-0.97%

call +0.97% · α +0.63%

$1.02

settled 6w ago

T+5d

+18.45%

call -18.45% · α -16.10%

$1.22

settled 6w ago

T+20d

+3.88%

call -3.88% · α +1.40%

$1.07

settled 17d ago

T+60d

—

call — · α —

—

in 6w

Price Chart

Loading chart...

Executive Summary

Rein Therapeutics priced a $50M underwritten public offering of 50M shares at $1.00/share, with an underwriter option for an additional 7.5M shares. The proceeds will fund the Phase 2 trial of LTI-03 in IPF and extend the cash runway into 2028. At a $36M market cap, this represents ~139% dilution, which is highly dilutive and bearish for existing shareholders.

Key Financial Metrics

Deal Value

$50.0M

Actionable Insight

Massive dilution event for a $36M market cap stock. Expect significant downward pressure on the stock price as the offering closes. Monitor for any insider participation or subsequent secondary offerings. The extended cash runway into 2028 reduces near-term bankruptcy risk but at a severe cost to current holders.

Key Facts

Priced 50M shares at $1.00/share for $50M gross proceeds
Underwriters have a 45-day option for an additional 7.5M shares
Offering represents ~139% dilution relative to pre-offering shares outstanding
Proceeds to fund Phase 2 trial of LTI-03 in IPF and extend cash runway into 2028
Offering expected to close on or about May 4, 2026
Konik Capital Partners acting as sole book-running manager

Financial Impact

~$50M gross proceeds with ~139% dilution to existing shareholders

dilutioncash runway

Risk Factors

Extreme dilution (~139%) will likely drive the stock price down sharply
Underwriter over-allotment option could add further dilution
Clinical-stage biotech with no approved products; Phase 2 trial risk remains
Potential for additional capital raises if cash runway proves insufficient

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

75% bullish (8 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3285633

8 reports for RNTX

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for RNTX — sortable, filterable
	Type				Now
Jun 8, 2026 6d ago	DEFA14A NEUTRAL ★ 3/10	$0.9402 awaiting T+20	awaiting T+20	—	$0.9580 (+1.89%)
May 4, 2026 5w ago	8-K BEARISH ★ 8/10	$1.02 $1.03	▼ −0.98%	▲ +3.97%	$0.9580 (+6.08%)
May 4, 2026 5w ago	424B5 BEARISH ★ 8/10	$1.02 $1.07	▼ −4.90%	▲ +0.74%	$0.9580 (+6.08%)
May 1, 2026 6w ago	Press Release BEARISH ★ 8/10	$1.03 $1.07	▼ −3.88%	▲ +1.40%	$0.9580 (+6.99%)
Apr 29, 2026 6w ago	Press Release NEUTRAL ★ 3/10	$1.28 $1.06	▼ −16.86%	▼ −22.32%	$0.9580 (−24.86%)
Apr 28, 2026 6w ago	S-1 NEUTRAL ★ 5/10	$1.28 $1.06	▼ −16.86%	▼ −22.32%	$0.9580 (−24.86%)
Apr 27, 2026 6w ago	10-K/A NEUTRAL ★ 3/10	$1.49 $1.07	▼ −28.19%	▼ −33.14%	$0.9580 (−35.70%)
Mar 3, 2026 14w ago	Press Release NEUTRAL ★ 5/10	$1.15 $1.30	▲ +13.04%	▲ +17.45%	$0.9580 (−16.70%)

US Market Status

Market Closed — Opens in 3h 55m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access